Apr 14, 2025
The paradigm shift from Non‐alcoholic Steatohepatitis (NASH) to Metabolic Dysfunction–associated Steatohepatitis (MASH) reflects a deeper understanding of the pathophysiology underpinning liver injury in the context of obesity, diabetes, and metabolic syndrome. This evolving nomenclature from NASH to MASH is more t...
Read More...
Oct 18, 2024
In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricat...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper